Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524476 NSE: ZILONPHARM Pharmaceuticals & Drugs | | Zillion Pharmachem Share Price
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524476 NSE: ZILONPHARM Pharmaceuticals & Drugs | | Zillion Pharmachem Share Price
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.


Zillion Pharmachem was incorporated on Aprril 24, 1992. It was promoted by Amit Shah, Bina Shah and Prafulchandra Barot. ZPL manufactures bulk drugs such as antendol, nifedipine, chloro pheniramine, trimethoprim, propanolol HCl and formulations such as ointments, injectables, syrups, capsules, tablets. It markets products under the brand names Zillion and Zee.
It entered into collaboration with Cuba Pharma Havana, Cuba, for products like Hepatitis B Surface Antigen vaccine, Streptokines, Facdermin cream, Meningocolol vaccine B & C, AIDS testing kits, and monoclonal antibiotics. ZPL has export orders worth Rs. 8.5 cr on hand. Export orders amounting to full capacity utilisation have been received from Dubai, Saudi Arabia, Indonesia, Singapore, Thailand, etc
The scrip of the company is suspended for trading since November 30, 2007.
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: